Identifying effectiveness in "the old old": Principles and values in the age of clinical trials

Science Technology and Human Values

Volumn 34, Issue 5, 2009, Pages 607-628

  Will, Catherine M ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Age; Extrapolation; Medical evidence; Pharmaceuticals

Indexed keywords

EID: 70249140951     PISSN: 01622439     EISSN: 15528251     Source Type: Journal    
DOI: 10.1177/0162243909340261     Document Type: Article

References (49)

1. Antman, E. M., J. Lau, B. Kupelnick, F. Mosteller, and T. C. Chalmers. 1992. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. Journal of the American Medical Association 268:240-8.
2. Armstrong, D. 2002. Clinical autonomy, individual and collective: The problem of changing doctors' behaviour. Social Science & Medicine 55 (10):1771-7.
3. Ashmore, M., M. Mulkay, and T. Pinch. 1989. Health and efficiency: A sociology of health economics. Milton Keynes and Philadelphia: Open University Press.
4. Ashmore, M., S. D. Brown, and K. Macmillan. 2005. Lost in the mall with Mesmer and Wundt: Demarcations and demonstrations in the psychologies. Science, Technology, & Human Values 30 (1):76-110.
5. Blue Cross and Blue Shield Association Technology Evaluation Center. 2007. Special report: The efficacy and safety of statins in the elderly. Assessment program. 21 vols. No. 12. http://www.bcbs.com/blueresources/tec/vols/21/special-report-the-efficacy.html (accessed July 31, 2008).
6. Market devices, eds., M. Callon, Y. Millo, and F. Muniesa. London: Blackwell.
7. Cambrosio, A., P. Keating, T. Schlich, and G. Weisz. 2006. Regulatory objectivity and the generation and management of evidence in medicine. Social Science & Medicine 63 (1):189-99.
8. Cholesterol Treatment Trialists Collaboration. 2005. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 366 (9493):1267-78.
9. Cochrane, A. L. 1972. Effectiveness and efficiency. Random reflections on health services. London: Nuffield Provincial Hospitals Trust.
10. Collins, H. M. 1992. Changing order. Replication and induction in scientific practice. Chicago and London: University of Chicago Press. Original edition, 1985.
11. Coulter, A., and C. Ham, eds. 2000. The global challenge of health care rationing. Buckingham: Open University Press.
12. Culyer, A. J. 2006. NICE's use of cost effectiveness as an exemplar of a deliberative process. Health Economics, Policy and Law 1:299-318.
13. Davies, C., M. Weatherell, and E. Barnett. 2006. Citizens at the centre. Deliberative participation in healthcare decisions. Bristol: Policy Press.
14. Dodier, N., and A. Camus. 1998. Openness and specialisation: Dealing with patients in a hospital emergency service. Sociology of Health & Illness 20 (4):413-44.
15. Epstein, S. 1995. The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Science, Technology, & Human Values 20 (4):408-37.
16. Epstein, S. 2007. Inclusion. The politics of difference in medical research. Chicago and London: University of Chicago Press.
17. Garber, A. M. 2004. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs 23 (4):W284.
18. Goldstein, M. R. 2003. The PROSPER trial. The Lancet 361 (9355):427.
19. Governing medicine: theory and practice, eds., A. Gray, and S. Harrison. Maidenhead and New York: Open University Press.
20. Harrison, S. 1998. The politics of evidence-based medicine in the United Kingdom. Policy and Politics 26 (1):15-31.
21. House of Commons Select Committee on Health. 2007. Written evidence on NICE. London: HMSO. http://www.publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we41.htm (accessed July 31, 2008).
22. Hughes, D., and L. Griffiths. 1996. 'But if you look at the coronary anatomy. . . ': Risk and rationing in cardiac surgery. Sociology of Health & Illness 18:172-97.
23. Latimer, J., K. Featherstone, P. Atkinson, A. Clarke, D. T. Pilz, and A. Shaw. 2006. Rebirthing the clinic: The interaction of clinical judgement and genetic technology in the production of medical science. Science, Technology, & Human Values 31 (5):599-630.
24. Marks, H. 1997. The progress of experiment: Science and therapeutic reform in the United States. 1900-1990. Cambridge: Cambridge University Press.
25. Milewa, T. 2006. Health technology adoption and the politics of governance in the UK. Social Science & Medicine 63 (12):3102-12.
26. National Institute for Clinical Excellence. 2002. Report of the first meeting of the Citizens Council. London: NICE. www.nice.org.uk (accessed July 31, 2008).
27. National Institute for Clinical Excellence. 2004. Scientific and social value judgements. London: NICE. www.nice.org.uk (accessed July 10, 2007).
28. National Institute for Health and Clinical Excellence. 2005a. Appraisal consultation document: Coronary heart disease-statins. London: NICE. www.nice.org.uk (accessed July 31, 2008).
29. National Institute for Health and Clinical Excellence. 2005b. Summary table of consultee and commentators comments on the ACD: Cardiovascular disease-statins. London: NICE. www.nice.org.uk (accessed July 31, 2008).
30. National Institute for Health and Clinical Excellence. 2005c. Summary table of non-consultee and non-commentator comments on the ACD: Cardiovascular disease-statins. London: NICE. www.nice.org.uk (accessed July 31, 2008).
31. National Institute for Clinical Excellence. 2005d. Addendum: School of Health and Related Research, University of Sheffield report on additional analyses of the incremental cost-effectiveness of statins. London: NICE. www.nice.org.uk (accessed July 31, 2008).
32. National Institute for Clinical Excellence. 2005e. Social value judgements. Guidelines for the Institute and its Advisory Committees development of NICE guidance. Draft presented to the board in January 2005. London: NICE. www.nice.org.uk (accessed July 31, 2008).
33. National Institute for Health and Clinical Excellence. 2005f. Social value judgements. Principles for the development of NICE guidance. Post consultation draft, September 2005. London: NICE. www.nice.org.uk (accessed July 10, 2007).
34. National Institute for Health and Clinical Excellence. 2005g. Social value judgements. Principles for the development of NICE guidance. London: NICE. www.nice.org.uk (accessed July 31, 2008).
35. National Institute for Health and Clinical Excellence. 2006. Cardiovascular disease-statins. TA94. London: NICE. www.nice.org.uk (accessed July 31, 2008).
36. National Institute for Health and Clinical Excellence. 2007. Memorandum of evidence to the health select committee. London: NICE. www.nice.org.uk (accessed July 31, 2008).
37. National Institute for Clinical Excellence Citizens Council. 2004. Report on age. London: NICE. www.nice.org.uk (accessed May 24, 2007).
38. Pope, C. 2003. Resisting evidence: the study of evidence-based medicine as a contemporary social movement. Health: An Interdisciplinary Journal 7 (3):267-82.
39. Porter, T. 1995. Trust in numbers: The pursuit of objectivity in science and public life. Princeton, New Jersey: Princeton University Press.
40. PROSPER Study Group. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. The Lancet 360 (9346):1623-30.
41. Richards, E. 1988. The politics of therapeutic evaluation. The vitamin C and cancer controversy. Social Studies of Science 18 (4):653-701.
42. Richards, E. 1991. Vitamin C and cancer. Medicine or politics? New York: St. Martins Press.
43. Sjögren, E., and C.-F. Helgesson. 2007. The Q(u)ALYfying hand: Health economics and medicine in the shaping of Swedish markets for subsidized pharmaceuticals. In Market devices, eds., M. Callon, Y. Millo, and F. Muniesa, 215-40. London: Blackwell.
44. Stefanec, T. 2003. The PROSPER trial. The Lancet 361 (9355):427.
45. Syrett, K. 2003. A technocratic fix to the "legitimacy problem"? The Blair government and health care rationing in the United Kingdom. Journal of Health Politics, Policy and Law 28 (4):715-46.
46. Tanenbaum, S. J. 1994. Knowing and acting in medical practice: The epistemological politics of outcomes research. Journal of Health Politics, Policy and Law 19 (1):27-44.
47. Timmermans, S., and M. Berg. 2003. The gold standard. The challenge of evidence-based medicine and standardisation in health care. Philadelphia: Temple University Press.
48. Will, C. 2005. Arguing about the evidence: Readers, writers and inscription devices in coronary heart disease risk assessment. Sociology of Health & Illness 27 (6):780-801.
49. Will, C. 2007. The alchemy of clinical trials. Biosocieties 2 (1):85-100.